Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume $1.91 -0.02 (-1.04%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Akebia Therapeutics Short Interest DataAkebia Therapeutics (AKBA) has a short interest of 16.57 million shares, representing 7.92% of the float (the number of shares available for trading by the public). This marks a 11.36% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.0, indicating that it would take 5.0 days of the average trading volume of 2.81 million shares to cover all short positions.Current Short Interest16,570,000 sharesPrevious Short Interest14,880,000 sharesChange Vs. Previous Month+11.36%Dollar Volume Sold Short$37.45 millionShort Interest Ratio5.0 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares236,231,000 sharesShort Percent of Float7.92%Today's Trading Volume3,574,507 sharesAverage Trading Volume2,806,735 sharesToday's Volume Vs. Average127% Short Selling Akebia Therapeutics? Sign up to receive the latest short interest report for Akebia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAKBA Short Interest Over TimeAKBA Days to Cover Over TimeAKBA Percentage of Float Shorted Over Time Remove Ads Akebia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202516,570,000 shares $37.45 million +11.4%7.9%5 $2.26 2/28/202514,880,000 shares $27.53 million -0.7%7.1%6.8 $1.85 2/15/202514,980,000 shares $31.91 million +3.7%7.2%6.8 $2.13 1/31/202514,450,000 shares $32.37 million -19.7%N/A6.4 $2.24 1/15/202517,990,000 shares $34.90 million +7.9%N/A7.3 $1.94 12/31/202416,680,000 shares $31.69 million +18.6%N/A7.9 $1.90 12/15/202414,070,000 shares $26.03 million +21.7%N/A7.1 $1.85 11/30/202411,560,000 shares $23.81 million -3.3%N/A6.2 $2.06 11/15/202411,960,000 shares $21.41 million -19.4%N/A6.5 $1.79 10/31/202414,840,000 shares $24.63 million -16.1%N/A8.1 $1.66 Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202417,680,000 shares $23.16 million -6.0%N/A10.6 $1.31 9/30/202418,800,000 shares $24.82 million -1.4%N/A10.1 $1.32 9/15/202419,060,000 shares $27.83 million -0.1%N/A7.2 $1.46 8/31/202419,070,000 shares $29.56 million +0.6%N/A6.9 $1.55 8/15/202418,950,000 shares $27.29 million +5.9%N/A6.6 $1.44 7/31/202417,890,000 shares $24.69 million -4.1%N/A5.9 $1.38 7/15/202418,660,000 shares $24.44 million +42.3%N/A5.8 $1.31 6/30/202413,110,000 shares $13.37 million +6.6%N/A4 $1.02 6/15/202412,300,000 shares $13.16 million -6.5%N/A2.7 $1.07 5/31/202413,160,000 shares $14.74 million +12.5%N/A2.7 $1.12 5/15/202411,700,000 shares $13.81 million -1.4%N/A2.3 $1.18 4/30/202411,860,000 shares $14.94 million -13.4%N/A2.4 $1.26 4/15/202413,690,000 shares $19.03 million +2.2%N/A2.9 $1.39 3/31/202413,400,000 shares $24.52 million +32.3%N/A3 $1.83 3/15/202410,130,000 shares $17.22 million +24.9%N/A3.4 $1.70 2/29/20248,110,000 shares $12.81 million +1.4%N/A4 $1.58 2/15/20248,000,000 shares $11.76 million -8.9%N/A4.5 $1.47 1/31/20248,780,000 shares $14.75 million +12.1%N/A5.4 $1.68 1/15/20247,830,000 shares $12.14 million -0.5%N/A5 $1.55 12/31/20237,870,000 shares $9.76 million +7.4%N/A5.3 $1.24 12/15/20237,330,000 shares $8.43 million -18.7%N/A5.5 $1.15 11/30/20239,010,000 shares $9.55 million -8.8%N/A6.9 $1.06 11/15/20239,880,000 shares $9.88 million -4.3%N/A6.8 $1.00 10/31/202310,320,000 shares $9.08 million +33.2%N/A6.8 $0.88 10/15/20237,750,000 shares $7.03 million +6.5%N/A4.5 $0.91 9/30/20237,280,000 shares $8.30 million +0.7%N/A4.4 $1.14 9/15/20237,230,000 shares $9.11 million +24.4%N/A4.1 $1.26 8/31/20235,810,000 shares $8.08 million -14.1%N/A3.1 $1.39 8/15/20236,760,000 shares $8.86 million +10.3%N/A3.2 $1.31 7/31/20236,130,000 shares $10.24 million +13.7%N/A2.8 $1.67Why Buffett and 100 members of Congress are Piling into this One Investment (Ad)While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.Don't know where to start investing in AI? Check out my latest investor briefing. 7/15/20235,390,000 shares $5.71 million +11.4%N/A2.9 $1.06 6/30/20234,840,000 shares $4.43 million +11.3%N/A2.7 $0.92 6/15/20234,350,000 shares $4.96 million -15.5%N/A2.5 $1.14 5/31/20235,150,000 shares $5.36 million +26.5%N/A3 $1.04 5/15/20234,070,000 shares $4.44 million -9.6%N/A2.4 $1.09 4/30/20234,500,000 shares $4.09 million -20.8%N/A2.4 $0.91 4/15/20235,680,000 shares $3.57 million +0.4%N/A2.9 $0.63 3/31/20235,660,000 shares $3.17 million -15.3%N/A2.8 $0.56 3/15/20236,680,000 shares $4.49 million -20.3%N/A3 $0.67 2/28/20238,380,000 shares $7.06 million +82.6%N/A3.5 $0.84 2/15/20234,590,000 shares $4.07 million +38.3%N/A2 $0.89 1/31/20233,320,000 shares $2.09 million -28.1%N/A1.7 $0.63 1/15/20234,620,000 shares $3.21 million -0.9%N/A2.7 $0.70 12/30/20224,660,000 shares $2.69 million -0.4%N/A2.7 $0.58 12/15/20224,680,000 shares $2.12 million -2.9%N/A3.1 $0.45 11/30/20224,820,000 shares $1.30 million -12.5%N/A3.4 $0.27 11/15/20225,510,000 shares $1.41 million -6.9%N/A3.8 $0.26 10/31/20225,920,000 shares $1.51 million -5.9%N/A3.4 $0.25 10/15/20226,290,000 shares $1.82 million -13.4%N/A2.7 $0.29 9/30/20227,260,000 shares $2.30 million -5.8%N/A2.6 $0.32 9/15/20227,710,000 shares $2.85 million -3.5%N/A1.1 $0.37 8/31/20227,990,000 shares $2.91 million -14.5%N/A1 $0.36 8/15/20229,340,000 shares $3.87 million -18.5%N/A1 $0.41 7/31/202211,460,000 shares $4.48 million +1.4%N/A1.1 $0.39 7/15/202211,300,000 shares $4.77 million +19.5%N/A1 $0.42 6/30/20229,460,000 shares $3.34 million -39.6%N/A0.7 $0.35 6/15/202215,660,000 shares $5.53 million -11.9%N/A1.2 $0.35 5/31/202217,780,000 shares $6.58 million -8.1%N/A1.5 $0.37 5/15/202219,340,000 shares $8.68 million +1.2%N/A1.8 $0.45 4/30/202219,120,000 shares $7.94 million +12.3%N/A1.9 $0.42 4/15/202217,020,000 shares $9.16 million -20.5%N/A1.9 $0.54 3/31/202221,410,000 shares $15.37 million +44.1%N/A3 $0.72 3/15/202214,860,000 shares $34.18 million +12.9%N/A3.8 $2.30 2/28/202213,160,000 shares $28.43 million +7.6%N/A3.5 $2.16 2/15/202212,230,000 shares $22.38 million +9.0%N/A3.6 $1.83 1/31/202211,220,000 shares $22.33 million +9.9%N/A3.5 $1.99 1/15/202210,210,000 shares $22.46 million -10.0%N/A3.4 $2.20 12/31/202111,350,000 shares $25.65 million -4.2%N/A4.1 $2.26 12/15/202111,850,000 shares $29.03 million +4.1%N/A4.6 $2.45 11/30/202111,380,000 shares $30.84 million +10.3%N/A5.5 $2.71 11/15/202110,320,000 shares $29.62 million -11.2%N/A5.1 $2.87 10/29/202111,620,000 shares $33.35 million +1.9%N/A5.8 $2.87 10/15/202111,400,000 shares $32.49 million -10.2%N/A5.3 $2.85 9/30/202112,690,000 shares $36.55 million +1.5%N/A4.1 $2.88 9/15/202112,500,000 shares $34.75 million -6.6%N/A3.9 $2.78 8/31/202113,380,000 shares $39.34 million +2.8%N/A3.7 $2.94 8/13/202113,010,000 shares $32.79 million -6.9%N/A3.4 $2.52 7/30/202113,980,000 shares $34.53 million -11.0%N/A3.6 $2.47 7/15/202115,700,000 shares $52.12 million +2.9%10.3%4.1 $3.32 6/30/202115,260,000 shares $57.84 million -2.2%10.0%4.6 $3.79Why Buffett and 100 members of Congress are Piling into this One Investment (Ad)While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.Don't know where to start investing in AI? Check out my latest investor briefing. 6/15/202115,610,000 shares $54.95 million -3.0%10.2%4.5 $3.52 5/28/202116,090,000 shares $56.48 million -11.7%10.6%4.5 $3.51 5/14/202118,220,000 shares $60.67 million -0.3%N/A4.3 $3.33 4/30/202118,280,000 shares $59.41 million -7.2%N/A3.6 $3.25 4/15/202119,690,000 shares $61.33 million -7.6%N/A3.3 $3.12 3/31/202121,300,000 shares $65.92 million -15.2%N/A3.3 $3.10 3/15/202125,130,000 shares $90.72 million -1.5%N/A3.7 $3.61 2/26/202125,500,000 shares $88.49 million -3.2%N/A3.7 $3.47 2/12/202126,350,000 shares $125.69 million -4.0%N/A4 $4.77 1/29/202127,450,000 shares $94.02 million -4.8%N/A4.4 $3.43 1/15/202128,820,000 shares $91.36 million +0.5%N/A4.5 $3.17 12/31/202028,680,000 shares $85.75 million +20.9%N/A4.4 $2.99 12/15/202023,730,000 shares $75.46 million +0.8%N/A3.7 $3.18 11/30/202023,540,000 shares $79.80 million -6.2%N/A3.3 $3.39 11/15/202025,100,000 shares $63.75 million -6.1%N/A3 $2.54 10/30/202026,730,000 shares $60.68 million +7.7%N/A3.4 $2.27 10/15/202024,830,000 shares $88.89 million +12.0%N/A3.7 $3.58 9/30/202022,170,000 shares $55.65 million +141.8%N/A4.3 $2.51 9/15/20209,170,000 shares $24.21 million +12.4%N/A2 $2.64 8/31/20208,160,000 shares $84.95 million -10.0%N/A2.4 $10.41 8/14/20209,070,000 shares $95.51 million -5.2%N/A6.9 $10.53 7/31/20209,570,000 shares $106.90 million -1.8%N/A6.5 $11.17 7/15/20209,740,000 shares $120.29 million +1.0%N/A5.6 $12.35 6/30/20209,640,000 shares $122.43 million +61.5%N/A5.5 $12.70 6/15/20205,970,000 shares $72.42 million +18.5%N/A3.7 $12.13 5/29/20205,040,000 shares $58.67 million -21.3%N/A3 $11.64 5/15/20206,400,000 shares $79.49 million -16.0%N/A3.7 $12.42 4/30/20207,620,000 shares $61.72 million +3.8%N/A4.6 $8.10 4/15/20207,340,000 shares $53.36 million +8.3%N/A5.3 $7.27 3/31/20206,780,000 shares $52.27 million -6.5%5.8%4.4 $7.71 AKBA Short Interest - Frequently Asked Questions What is Akebia Therapeutics' current short interest? Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 16,570,000 shares of AKBA short. 7.92% of Akebia Therapeutics' shares are currently sold short. Learn More on Akebia Therapeutics' current short interest. What is a good short interest ratio for Akebia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 5.0. Learn More on Akebia Therapeutics's short interest ratio. Which institutional investors are shorting Akebia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Akebia Therapeutics: Wolverine Trading LLC, Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Akebia Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.92% of Akebia Therapeutics' floating shares are currently sold short. Is Akebia Therapeutics' short interest increasing or decreasing? Akebia Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 16,570,000 shares, an increase of 11.4% from the previous total of 14,880,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akebia Therapeutics' short interest compare to its competitors? 7.92% of Akebia Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Akebia Therapeutics: Travere Therapeutics, Inc. (14.90%), Janux Therapeutics, Inc. (21.18%), Disc Medicine, Inc. (10.29%), Agios Pharmaceuticals, Inc. (6.16%), Apogee Therapeutics, Inc. (22.09%), Mesoblast Limited (2.57%), Vera Therapeutics, Inc. (14.81%), Galapagos NV (4.19%), Kiniksa Pharmaceuticals, Ltd. (9.36%), Schrödinger, Inc. (13.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Akebia Therapeutics stock? Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akebia Therapeutics? A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further. How often is Akebia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies TVTX Short Interest Data JANX Short Interest Data IRON Short Interest Data AGIO Short Interest Data APGE Short Interest Data MESO Short Interest Data VERA Short Interest Data GLPG Short Interest Data KNSA Short Interest Data SDGR Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKBA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
